Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Vincent Khoo

Showing results (31-40 of 116) with videos related to

Pageof 12
Sort By:
Cancers|November 12, 2013
Toxicity and Long-Term Outcomes of Dose-Escalated Intensity Modulated Radiation Therapy to 74Gy for Localised Prostate Cancer in a Single Australian CentreJoseph Sia, Daryl Lim Joon, Angela Viotto, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|November 27, 2007
Outcome of early detection and radiotherapy for occult spinal cord compressionRamachandran Venkitaraman, Yolanda Barbachano, David P Dearnaley, et al.
BJU International|September 12, 2019
Prostate-specific membrane antigen-positron emission tomography/computed tomography (PSMA-PET/CT)-guided stereotactic ablative body radiotherapy for oligometastatic prostate cancer: a single-institution experience and review of the published literatureWee Loon Ong, Tze Lui Koh, Daryl Lim Joon, et al.
Technical Innovations & Patient Support in Radiation Oncology|March 11, 2020
Clinical and dosimetric risk stratification for patients at high-risk of feeding tube use during definitive IMRT for head and neck cancerJames E Jackson, Nigel J Anderson, Morikatsu Wada, et al.
BJU International|November 8, 2008
Prostate-specific antigen (PSA) kinetics in untreated, localized prostate cancer: PSA velocity vs PSA doubling timeMichael K Ng, Nicholas Van As, Karen Thomas, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|January 30, 2017
An orally bioavailable Chk1 inhibitor, CCT244747, sensitizes bladder and head and neck cancer cell lines to radiationRadhika Patel, Holly E Barker, Joan Kyula, et al.
Journal of Medical Imaging and Radiation Oncology|April 3, 2014
MRI scans significantly change target coverage decisions in radical radiotherapy for prostate cancerJoe H Chang, Daryl Lim Joon, Brandon T Nguyen, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|September 20, 2005
Towards individualised radiotherapy for Stage I seminomaJarad M Martin, Daryl Lim Joon, Nicole Ng, et al.
International Journal of Radiation Oncology, Biology, Physics|December 1, 2025
Predictors of Long-Term Disease-Free Survival With Stereotactic Body Radiation Therapy for Oligometastatic Prostate CancerBinnaz Yasar, Ewan Chapman, Helen Taylor, et al.
International Journal of Radiation Oncology, Biology, Physics|January 23, 2010
Expression of Bcl-2, p53, and MDM2 in localized prostate cancer with respect to the outcome of radical radiotherapy dose escalationRoy Vergis, Catherine M Corbishley, Karen Thomas, et al.
Pageof 12

Showing results (31-40 of 116) with videos related to

Sort By:
Pageof 12
Cancers|November 12, 2013
Toxicity and Long-Term Outcomes of Dose-Escalated Intensity Modulated Radiation Therapy to 74Gy for Localised Prostate Cancer in a Single Australian CentreJoseph Sia, Daryl Lim Joon, Angela Viotto, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|November 27, 2007
Outcome of early detection and radiotherapy for occult spinal cord compressionRamachandran Venkitaraman, Yolanda Barbachano, David P Dearnaley, et al.
BJU International|September 12, 2019
Prostate-specific membrane antigen-positron emission tomography/computed tomography (PSMA-PET/CT)-guided stereotactic ablative body radiotherapy for oligometastatic prostate cancer: a single-institution experience and review of the published literatureWee Loon Ong, Tze Lui Koh, Daryl Lim Joon, et al.
Technical Innovations & Patient Support in Radiation Oncology|March 11, 2020
Clinical and dosimetric risk stratification for patients at high-risk of feeding tube use during definitive IMRT for head and neck cancerJames E Jackson, Nigel J Anderson, Morikatsu Wada, et al.
BJU International|November 8, 2008
Prostate-specific antigen (PSA) kinetics in untreated, localized prostate cancer: PSA velocity vs PSA doubling timeMichael K Ng, Nicholas Van As, Karen Thomas, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|January 30, 2017
An orally bioavailable Chk1 inhibitor, CCT244747, sensitizes bladder and head and neck cancer cell lines to radiationRadhika Patel, Holly E Barker, Joan Kyula, et al.
Journal of Medical Imaging and Radiation Oncology|April 3, 2014
MRI scans significantly change target coverage decisions in radical radiotherapy for prostate cancerJoe H Chang, Daryl Lim Joon, Brandon T Nguyen, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|September 20, 2005
Towards individualised radiotherapy for Stage I seminomaJarad M Martin, Daryl Lim Joon, Nicole Ng, et al.
International Journal of Radiation Oncology, Biology, Physics|December 1, 2025
Predictors of Long-Term Disease-Free Survival With Stereotactic Body Radiation Therapy for Oligometastatic Prostate CancerBinnaz Yasar, Ewan Chapman, Helen Taylor, et al.
International Journal of Radiation Oncology, Biology, Physics|January 23, 2010
Expression of Bcl-2, p53, and MDM2 in localized prostate cancer with respect to the outcome of radical radiotherapy dose escalationRoy Vergis, Catherine M Corbishley, Karen Thomas, et al.
Pageof 12